Tarsus Pharmaceuticals, Inc.
TARS
$59.83
$0.180.30%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 6.85% | 27.78% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.85% | 27.78% | |||
| Cost of Revenue | 9.62% | 17.77% | |||
| Gross Profit | 6.19% | 30.39% | |||
| SG&A Expenses | 4.40% | 20.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.34% | 19.83% | |||
| Operating Income | 23.24% | 45.10% | |||
| Income Before Tax | 26.91% | 49.83% | |||
| Income Tax Expenses | 14.23% | -- | |||
| Earnings from Continuing Operations | 16.79% | 33.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 16.79% | 33.47% | |||
| EBIT | 23.24% | 45.10% | |||
| EBITDA | 24.53% | 46.46% | |||
| EPS Basic | 17.12% | 33.75% | |||
| Normalized Basic EPS | -209.34% | 86.08% | |||
| EPS Diluted | 17.12% | 33.75% | |||
| Normalized Diluted EPS | -209.34% | 86.08% | |||
| Average Basic Shares Outstanding | 0.40% | 0.42% | |||
| Average Diluted Shares Outstanding | 0.40% | 0.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||